Warren G, McKendrick M, Peet M
The University of Sheffield, Section of Psychiatry, Northern General Hospital, UK.
Acta Neurol Scand. 1999 Feb;99(2):112-6. doi: 10.1111/j.1600-0404.1999.tb00667.x.
To replicate the treatment study by Behan et al. (1990) using current research criteria for Chronic Fatigue Syndrome (CFS).
Fifty patients who fulfilled the Oxford Criteria for CFS were randomly allocated to treatment with either Efamol Marine or placebo for 3 months. They were seen monthly and completed a physical symptoms checklist and the Beck Inventory for Depression and reported if they were the same, better or worse at the end of the study.
Symptoms generally improved with time but not significantly and there were no significant differences between the treatment and placebo groups. Pretreatment red-cell membrane (RBC) lipids of patients compared with age-and sex-matched normal controls showed no significant differences.
The results of this study contrast sharply with the previous study where 85% of patients had a clinically significant improvement of symptoms with Efamol Marine over a 3-month treatment period.
采用当前慢性疲劳综合征（CFS）的研究标准，重复Behan等人（1990年）的治疗研究。
50名符合牛津CFS标准的患者被随机分配接受Efamol Marine或安慰剂治疗3个月。每月对他们进行检查，他们完成一份身体症状清单和贝克抑郁量表，并报告在研究结束时症状是相同、改善还是恶化。
症状总体上随时间有所改善，但不显著，治疗组和安慰剂组之间没有显著差异。与年龄和性别匹配的正常对照组相比，患者治疗前的红细胞膜（RBC）脂质无显著差异。
本研究结果与之前的研究形成鲜明对比，在之前的研究中，85%的患者在3个月的治疗期内使用Efamol Marine后症状有临床显著改善。
